Han et al. (2020)  Case study/People's Hospital in Wuwei  A 47‐year‐old man/smoking for 20 years/no alcohol abuse  RT‐PCR, CT  Nasopharyngeal swab specimens  Confirmed SARS‐CoV‐2/returned to Wuwei city on January 18 from Wuhan city by car  Blood:
decreased lymphocytes, increased CRP, slightly elevated fibrinogen, neutrophil, LDH, and fibrinogen
PCR: positive for expression of RdRPN, N and E genes
CT: multiple patchy high‐density shadows scattered mainly in the border regions of lungs, solid changes, GGO changes, slightly thickened pleura  Fever, cough productive of white phlegm, bosom frowsty, stuffy/runny noses, vertigo, fatigue, chest tightness, nausea, expiratory dyspnea, poor diet, lethargy/hypertension grade 2 and T2D  –  –  Therapy:
combination therapy including:
Lopinavir/Ritonavir (800/200 mg daily), methylprednisolone (40 mg daily), recombinant human interferon α‐2b (10 million IU daily), ambroxol hydrochloride (60 mg daily) moxifloxacin hydrochloride (0.4 g daily), high flow humidification oxygen inhalation therapy, treatment of blood glucose, blood pressure, and rehydration therapy
Results interpretation: the persistent negative results of SARS‐CoV‐2 on days 6 and 7, normal TLC, lung lesions partially absorbed, The patient discharged. Laboratory tests like TLC are necessary, CT combined with RT‐PCR is helpful, Lopinavir/Ritonavir are effective after failure of methylprednisolone/interferon alfa‐2b